
Neurologist

No OPD information available
Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Primary Lateral Sclerosis
Chorea
Cramp-Fasciculation Syndrome
Dementia
Drug Induced Dyskinesia
Dysarthria
Gastrostomy
Huntington Disease
Movement Disorders
Spasmodic Dysphonia
Susan Mathers is a female healthcare provider who specializes in helping patients with various conditions like Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis, Chorea, and more. She is skilled in treating movement disorders, dementia, and dysarthria. Susan also assists patients with procedures like gastrostomy for feeding support.
Patients trust Susan Mathers because of her excellent communication skills and compassionate approach to care. She takes the time to listen to their concerns and explain treatment options in a way that is easy to understand. Patients appreciate her dedication to staying informed about the latest medical advancements and research in her field.
Susan Mathers collaborates closely with her colleagues and other medical professionals to provide the best possible care for her patients. She values teamwork and believes in a multidisciplinary approach to healthcare. Her relationships with other healthcare providers enhance the quality of care she delivers.
Through her work, Susan Mathers has positively impacted many patients' lives. Her expertise and dedication have helped improve the health and well-being of those she cares for. She is also actively involved in research, with notable publications in prestigious medical journals and ongoing participation in clinical trials aimed at advancing the understanding and treatment of ALS.
In summary, Susan Mathers is a dedicated healthcare provider who specializes in treating various neurological conditions. She is known for her excellent communication skills, commitment to staying updated with medical knowledge, collaborative approach to care, and positive impact on patients' lives.
Enrollment Status: Active not recruiting
Published: April 08, 2025
Intervention Type: Drug
Study Drug: Fasudil (WP-0512)
Study Phase: Phase 2
